JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Merck & Co., Inc. (NYSE:MRK) Stock

Key Points

• JPMorgan raised its price target on Merck from $135 to $140 and kept an overweight rating, implying about 13.1% upside from the current price.
• Other analysts have also been constructive on the stock, including BMO Capital Markets lifting its target to $142; MarketBeat shows an overall consensus rating of Moderate Buy with an average target of $133.94.
• Merck recently beat earnings expectations, reporting Q1 EPS of -$1.28 versus an expected -$1.47 and revenue of $16.29 billion, while analysts now expect about $5.17 EPS for the current year.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) had its price target increased by investment analysts at JPMorgan Chase & Co. from $135.00 to $140.00 in a research note issued to investors on Monday,Benzinga reports. The firm presently has an "overweight" rating on the stock. JPMorgan Chase & Co.'s price objective points to a potential upside of 13.10% from the stock's current price.

MRK has been the topic of several other reports. Citigroup assumed coverage on shares of Merck & Co., Inc. in a research report on Wednesday, May 6th. They issued a "neutral" rating and a $125.00 price objective on the stock. CICC Research assumed coverage on shares of Merck & Co., Inc. in a research report on Wednesday, June 24th. They set an "outperform" rating and a $138.00 price objective on the stock. Zacks Research raised shares of Merck & Co., Inc. from a "strong sell" rating to a "hold" rating in a report on Tuesday, March 17th. Cantor Fitzgerald reissued a "neutral" rating and issued a $120.00 target price on shares of Merck & Co., Inc. in a research note on Monday, July 6th. Finally, BMO Capital Markets raised their price target on Merck & Co., Inc. from $135.00 to $142.00 and gave the company an "outperform" rating in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $133.94.

Merck & Co., Inc. Price Performance

Shares of MRK traded up $0.24 during mid-day trading on Monday, reaching $123.78. 1,509,428 shares of the stock traded hands, compared to its average volume of 10,999,076. The firm has a fifty day moving average price of $118.83 and a 200 day moving average price of $116.36. The company has a market cap of $305.71 billion, a price-to-earnings ratio of 34.85, a price-to-earnings-growth ratio of 2.65 and a beta of 0.19. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02. Merck & Co., Inc. has a 1 year low of $76.66 and a 1 year high of $130.29.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, topping the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The business had revenue of $16.29 billion during the quarter, compared to analysts' expectations of $15.85 billion. During the same period in the previous year, the business earned $2.22 earnings per share. The firm's revenue was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, equities research analysts predict that Merck & Co., Inc. will post 5.17 earnings per share for the current year.

Institutional Investors Weigh In On Merck & Co., Inc.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Brighton Jones LLC grew its stake in shares of Merck & Co., Inc. by 29.5% in the fourth quarter. Brighton Jones LLC now owns 38,278 shares of the company's stock worth $3,808,000 after acquiring an additional 8,710 shares during the last quarter. Sivia Capital Partners LLC raised its holdings in shares of Merck & Co., Inc. by 52.2% during the second quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company's stock valued at $910,000 after purchasing an additional 3,941 shares during the last quarter. Diversify Advisory Services LLC lifted its holdings in Merck & Co., Inc. by 94.1% in the second quarter. Diversify Advisory Services LLC now owns 32,256 shares of the company's stock valued at $2,590,000 after acquiring an additional 15,636 shares during the period. Diversify Wealth Management LLC increased its holdings in Merck & Co., Inc. by 22.2% during the second quarter. Diversify Wealth Management LLC now owns 38,031 shares of the company's stock valued at $3,054,000 after buying an additional 6,897 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Merck & Co., Inc. by 111.7% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 681,128 shares of the company's stock worth $53,918,000 after purchasing an additional 359,356 shares during the period. 76.07% of the stock is currently owned by institutional investors.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.